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INTRODUCTION
Generally, nonsynostotic plagiocephaly is an asymmetrical con-
dition of the head caused by an extrinsic factor such as molding 
rather than by an intrinsic factor such as craniosynostosis [1]. 
Nonsynostotic plagiocephaly is also called deformational plagio-
cephaly, positional plagiocephaly, or the flat head syndrome [2].
The causes of nonsynostotic plagiocephaly can be divided into 
prenatal and postnatal causes. The prenatal causes include uter-
ine compression and intra-uterine constraint, and the postnatal 
causes include the sleeping position and congenital muscular 
torticollis. Among the causes of nonsynostotic craniosynostosis, 
sleeping position may be assumed to play a major role in the 
incidence of this condition. A study reported that the incidence 
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Background  It is known that nonsynostotic plagiocephaly does not spontaneously improve, 
and the craniofacial deformities that result from it. This study was conducted to analyze the 
effectiveness of helmet therapy for the nonsynostotic plagiocephaly patient, and to suggest 
a new treatment strategy based on this analysis.
Methods  A total of 108 pediatric patients who had undergone helmet therapy after being 
diagnosed with nonsynostotic plagiocephaly were included in this study. The patients were 
classified according to the initiation age of the helmet therapy, severity, and helmet wearing 
time. The treatment effect was compared using cranial vault asymmetry (CVA) and the cranial 
vault asymmetry index (CVAI), which were obtained from diagonal measurements before and 
after therapy. 
Results  The discrepancy of CVA and CVAI of all the patients significantly decreased after 
helmet therapy. According to the initiation time of helmet therapy, the treatment effect 
was best at 5 months old or less. The helmet wearing time per day was proportional to the 
treatment effect up to 20 hours. In addition, the rate of the successful treatment (final CVA 
≤5 mm) significantly decreased when the initiation age was 9.1 months or older and the 
treatment period was less than 7.83 months. 
Conclusions  This study showed the effectiveness of the helmet therapy for nonsynostotic 
plagiocephaly patients. Based on analysis of this study, helmet therapy should be started at the 
age of 9 months or younger for 7.83 months or more, and the helmet wearing time should be 
more than 20 hours a day.
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of nonsynostotic plagiocephaly in the U.S. has dramatically 
increased since the implementation of the “Back to sleep” cam-
paign, one of the regimens suggested by the American Academy 
of Pediatrics for preventing the sudden infant death syndrome 
[3]. 
Many studies have reported that nonsynostotic plagiocephaly 
does not spontaneously improve [4,5] and the craniofacial de-
formities such as asymmetry of the face and ear position, which 
result fron it, will also be permanent [6-11]. The asymmetric 
head caused by nonsynostotic plagiocephaly will worsen over 
time because the pediatric patient is usually positioned on 
the flattened area of the head in a supine position. Moreover, 
because its incidence rate is reported to be 1 in 300 newborn 
babies [12], the need for appropriate treatment for nonsynos-
totic plagiocephaly is becoming widely recognized. Treatment 
options for nonsynostotic plagiocephaly include head reposi-
tioning, helmet therapy, and surgery [13]. Among these, helmet 
therapy is most widely used. It can achieve treatment effects by 
inducing prominent areas to be retained passively and flattened 
areas to grow rapidly into the hollow space in the orthotic de-
vice [14]. Studies have reported that helmet therapy achieved 
about 3 times faster and better correction than head positioning 
alone [1,2,6,10,15]. However, no studies have reported on the 
effectiveness of helmet therapy in Asian or particularly Korean 
children because helmet therapy is not widely performed. Thus 
this study was conducted to analyze the effectiveness of helmet 
therapy for nonsynostotic plagiocephaly patients in the Repub-
lic of Korea.
METHODS
A total of 108 pediatric patients who had completed helmet 
therapy after being diagnosed with nonsynostotic plagiocephaly 
between 2008 and 2011 were included in this study. Of these 
108 patients, 75 were male (69.4%) and 33, female (30.6%). 
A three-dimensional (3D) computed tomography (CT) scan 
of each patient confirmed that craniosynostosis was not pres-
ent. The helmet was customized individually according to a 3D 
CT scan and the measurements of the patient’s head including 
the anteroposterior, bitemporal, and diagonal distances using a 
spreading caliper, and the circumference using a tapeline (Fig. 
1). Treatment effects can be achieved by inducing prominent 
areas to be retained passively and flattened areas to grow rapidly 
into the hollow space in the helmet [14]. According to the hel-
met therapy protocol of the authors’ hospital, if the difference 
between each diagonal distance was more than 10 mm, helmet 
therapy was strongly recommended. When a patient’s parents 
decided to undergo helmet therapy, the patients were followed 
up at 4- to 8-week intervals based on their ages and conditions. 
Three physicians measured the anteroposterior, bitemporal, and 
diagonal distances of the patient’s head using a spreading caliper 
and head circumference using a tapeline. The measurements 
from three physicians were averaged before entering the doc-
tor’s office on every follow-up visit. The patient’s parents were 
supposed to record the helmet wearing time everyday, and bring 
this form to the outpatient clinic. 
In each patient, the frontozygomatic-to-contralateral occipital 
(euryon) distance was measured on both sides using a spreading 
caliper. The distances were defined as diagonal A or B (A>B), 
and the cranial vault asymmetry (CVA) (diagonal A -diagonal 
B) and cranial vault asymmetry index (CVAI) ([diagonal A to 
diagonal B]/[diagonal A×100]) [14] were measured. Then 
the measured CVA and CVAI were compared with the initial 
measurements to assess the treatment effect and determine 
the termination of the therapy (Fig. 2). The patients were clas-
sified into group 1 (5 months or less, n=20), group 2 (6 to 8 
Fig. 1. Helmet for cranial molding therapy
The helmet was customized individually according to a 3D CT scan 
and the measurements of the patient’s head including anteroposterior, 
bitemporal, and diagonal distances using a spreading caliper, and 
circumference using a tapeline. The helmet can achieve treatment 
effects by inducing prominent areas to be retained passively and 
flattened areas to grow rapidly into the hollow space in the helmet. (A) 
The front, (B) the side of helmet.
A B
Fig. 2. Diagonal measurement of patient’s head
The frontozygomatic-to-contralateral occipital (euryon) distance was 
measured using spreading calipers on both sides of each patient. The 
distances were defined as diagonal A (fz A to eu A) and B (fz B to eu 
B) (A>B), after which the cranial vault asymmetry (CVA) (diagonal A 
to diagonal B) and cranial vault asymmetry index (CVAI) ([diagonal A 
to diagonal B]/[diagonal A×100]) were measured. CVA, cranial vault 
asymmetry; CVAI, cranial vault asymmetry index.
fzB
euB
euA
fzA
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on the change in the CVA that was measured during the helmet 
therapy, the tolerance of the patients, and the satisfaction of the 
patients’ parents. The data analysis was performed using PASW 
Statistics ver. 18.0 (IBM Co., Armonk, New York, USA). The 
patients were grouped based on the initiation age of the treat-
ment, the severity of head asymmetry, and their compliance 
level. The treatment effects of each group were compared using 
a paired sample T-test and a Wilcoxon signed rank test. The 
statistically significant level was set at P<0.05. The correlation 
between the treatment effect and the helmet wearing time was 
tested using a Pearson’s correlation test (P<0.05). We consid-
months, n=38), group 3 (9 to 11 months, n=31), and group 4 
(12 months, n=19), based on their initiation age of the helmet 
therapy (Table 1). In addition, the severity of the head asym-
metry was classified into mild (6 to 10 mm, n=15), moderate 
(11 to 15 mm, n=34), and severe (≥16 mm, n=59) based 
on the initial CVA (Table 2). The compliance of the patients 
was classified into poor (<15 hours, n=24), good (15 to 19 
hours, n=55), and excellent (≥20 hours, n=29), based on 
helmet wearing time in a day, which was obtained from the 
form that was filled out by the patient’s parents (Table 3). The 
treatment termination was decided on by the physician based 
Table 3. The effectiveness of helmet therapy according to the helmet wearing time
Compliance (hr) No. Duration (mean)
CVA CVAI (mean)
Initial Final P-value Initial Final P-value
Poor (<15)   24 7.27 18.0 6.8 0.0000 11.67 4.24 0.0000
Good (15-19)   55 6.92 16.0 4.6 0.0000 10.74 2.96 0.0000
Excellent (≥20)   29 5.29 14.4 3.2 0.0000 9.75 2.05 0.0000
Total 108 6.56 16.0 4.7 0.0000 10.68 3.00 0.0000
The patients were grouped based on their helmet wearing time a day (compliance). The patients with a helmet wearing time of less than 15 hours were grouped into the poor 
compliance group; 15-19 hours, into the good compliance group; and 20 hours or more, into the excellent compliance group. The correlation between the helmet wearing 
time and the treatment effect was analyzed via a Pearson correlation test. In the poor and good compliance groups, the initial to final CVA and the initial to final CVAI were 
proportional to the helmet wearing time (r=0.432, P=0.0349, and r=0.266, P=0.0499). In the excellent compliance group, the helmet wearing time was not significantly 
proportional to the change in the CVA and CVAI (r=-0.022 and P=0.9111). In addition, the treatment periods were 7.27, 6.92, and 5.29 months in the poor, good, and 
excellent compliance groups, respectively, which meant that the poorer compliance level was, the longer treatment period was (P=0.006).
CVA, cranial vault asymmetry; CVAI, cranial vault asymmetry index.
Table 1. The effectiveness of helmet therapy according to the starting age
Starting age (mo) No. Duration (mean) 
Compliance 
(mean)
CVA (mean) CVAI (mean)
Initial Final P-value Initial Final P-value
Group1 (≤5)         20 6.70 17.96 15.5 3.9 0.0001 10.97 2.61 0.0001
Group 2 (6-8)         38 6.12 17.40 16.3 4.8 0.0000 11.01 3.11 0.0000
Group 3 (9-11)         31 6.94 16.87 15.9 4.5 0.0000 10.35 2.84 0.0000
Group 4 (≥12)         19 6.66 15.63 16.3 5.6 0.0001 10.24 3.47 0.0001
Total       108 6.56 17.04 16.0 4.7 0.0000 10.68 3.00 0.0000
In the total of 108 pediatric patients, the mean treatment period with helmet therapy was 6.56 months, and the initial CVA and CVAI were 16.0 mm and 10.68%, respectively. 
The final CVA and CVAI were 4.7 mm and 3.00%, respectively. The changes were statistically significant (P<0.0001 and P<0.0001). Among the patient groups based on the 
initiation age of the treatment (Groups 1, 2, 3, and 4), the initial to final CVA and the initial to final CVAI were greatest in Group 1 and least in Group 4.
CVA, cranial vault asymmetry; CVAI, cranial vault asymmetry index.
Table 2. The effectiveness of helmet therapy according to the initial severity
Initial severity  
   group (mo) No.
Duration
(mean)
Compliance
(mean)
CVA (mean) CVAI (mean)
Initial Final P-value Initial Final P-value
Mild (6-10)        15 6.13 18.01 7.8 2.8 0.0006 5.40 1.80 0.0007
Moderate (11-15)        34 5.77 17.28 13.0 4.6 0.0000 8.76 2.95 0.0000
Severe (≥16)        59 7.12 16.65 19.8 5.3 0.0000 13.13 3.33 0.0000
Total      108 6.56 17.04 16.0 4.7 0.0000 10.68 3.00 0.0000
The severity of the head asymmetry was classified into mild (6-10 mm, n=15), moderate (11-15 mm, n=34), and severe (≥16 mm, n=59) based on the initial CVA. The change 
in the CVA and CVAI were greatest in the severe group and least in the mild group (P=0.0007 and P<0.0001).
CVA, cranial vault asymmetry; CVAI, cranial vault asymmetry index.
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ered a final CVA ≤5 mm to indicate a successful treatment. 
The changes in the successful treatment rate according to the 
treatment initiation age and the treatment period were analyzed 
using an receiver operating characteristic (ROC) curve with a 
95% confidence interval (CI).
RESULTS
Of the 108 patients, the mean initiation age was 9 months 
(range, 3 to 43 months), and the mean CVA and CVAI before 
the treatment were 16 mm (range, 6 to 30 mm) and 10.68% 
(range, 3.85% to 19.29%), respectively. The mean helmet wear-
ing time was 17 hours a day (24 hours), and the mean treatment 
period was 6.6 months. The mean CVA and CVAI after the 
treatment were 4.7 mm (range, 0 to 10 mm) and 3% (range, 0% 
to 6.85 %), respectively. The final CVA and CVAI significantly 
decreased compared with the initial CVA and CVAI (P<0.0001 
and P<0.0001) (Table 1, Fig. 3). When the patients were 
grouped based on their treatment initiation age into group 1 (5 
months or less, n=20), group 2 (6 to 8 months, n=38), group 
3 (9 to 11 months, n=31), and group 4 (12 months or more, 
n=19), the change in their CVA and CVAI was greatest in 
group 1 (initial CVA to final CVA=11.6 and initial CVAI to fi-
nal CVAI=8.36, P=0.0001 and P=0.0001), and least in group 
4 (initial CVA to final CVA=10.7 and initial CVAI to final 
CVAI=6.77, P=0.0001 and P=0.0001), which meant that the 
treatment effect was greater in the younger patients than in the 
older patients (Table 1).
Among the patient groups based on the initial CVA (mild [6 
to 10 mm, n=15], moderate [11 to 15 mm, n=34], and severe 
groups [≥16 mm, n=59]), the change was greatest in the se-
vere group (initial CVA to final CVA=14.5 and initial CVAI 
to final CVAI=9.8, P<0.0001 and P<0.0001) and least in the 
mild group (initial CVA to final CVA=5 and initial CVAI to 
final CVAI=3.6, P=0.0006 and P=0.0007). In addition, the 
treatment periods were 6.1, 5.8, and 7.1 months in the mild, 
moderate, and severe groups, respectively. The Pearson’s cor-
relation test of the correlation between the initial CVA and the 
treatment period showed that the greater the initial CVA was, 
the longer the treatment period was (r=0.06, P=0.040) (Table 
2), and this was statistically significant.
In addition, the patients were grouped based on helmet wearing 
time into the poor compliance group (<15 hours, n=24), good 
compliance group (15 to 19 hours, n=55), and excellent com-
pliance group (≥20 hours, n=29). In the poor and good com-
pliance groups, the longer the helmet wearing time was, the sig-
nificantly greater the initial to final CVA and initial to final CVAI 
were (r=0.432, P=0.0349, and r=0.266, P=0.0499); however, 
they were not significantly greater with longer helmet wearing in 
the excellent compliance group (r=-0.022, P=0.9111), accord-
ing to Pearson’s correlation test. These findings indicate that the 
treatment effect was proportional to the helmet wearing time 
up to 20 hours a day. However, the treatment effect was not pro-
portional to the helmet wearing time beyond 20 hours. In addi-
tion, the treatment periods were 7.27, 6.92, and 5.29 months in 
the poor, good, and excellent compliance groups, respectively, 
which meant that the poorer the compliance level was, the lon-
ger the treatment was needed (P=0.006) (Table 3). 
We considered a final CVA ≤5 mm as a successful treatment, 
and the rate of successful treatment was 73% (75 in total 108 
patients). When the initiation age of the helmet therapy was 9.1 
months, the area under the ROC curve was 0.633 which was in 
the 95% CI 0.535 to 0.724. This meant that the rate of successful 
treatment was statistically different at the point of 9.1 months 
(in other words, the patients who started helmet therapy young-
er than 9.1 months showed a higher success rate than those who 
Fig. 3. Photos and 3D CT: pre- and posttreatment
(A) The initial CVA and CVAI were 17 mm and 11.56%, respectively, which were measured using spreading calipers. (B) The CVA decreased by 12 mm 
(initial CVA, 17 mm; final CVA, 5 mm) and the CVAI decreased by 8.19% (initial CVAI, 11.56%; final CVAI, 3.37%). The treatment initiation age was 
6.3 months and the treatment period was 7.1 months. (C) Before the helmet therapy, a three-dimensional (3D) computed tomography (CT) scan was 
performed to confirm that craniosynostosis was not present. In the 3D CT scan, any discrepancy in the diagonal distances was noted. (D) When the 
helmet therapy was over, the 3D CT scan was performed again to assess the treatment effect. The posttreatment 3D CT scan showed the decreased 
discrepancy of the diagonal distances. CVA, cranial vault asymmetry; CVAI, cranial vault asymmetry index.
A B C D
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started older than 9.1 months) (Fig. 4). In addition, when the 
treatment period of the helmet therapy was 7.83 months, the 
area under the ROC curve was 0.607, which was in the 95% CI 
0.509 to 0.700. This means that the rate of successful treatment 
had a statistical difference above and below the point of 7.83 
months (the patients who had worn the helmet more than 7.83 
months showed a higher success rate than those who word it 
less than 7.83 months) (Fig. 5).
DISCUSSION
The treatment effect of helmet therapy for nonsynostotic pla-
giocephaly in pediatric patients has been reported in many stud-
ies [1,6,10,13-17] since the first report by Clarren et al. [18] in 
1979. It has been reported that nonsynostotic plagiocephaly 
would not spontaneously improve [4,5] and that complications 
related to helmet therapy, such as contact dermatitis, miliaria, 
and skin rash, were not severe [15,19,20]. However, it could be 
possible that helmet wearing would result in developing severe 
complications such as focal pressure injury. In this study, the 
authors reported good treatment effects of helmet therapy by 
comparing initial CVI and CVAI with final CVI and CVAI. 
However, there is no quantified standard measurement for the 
assessment of the outcome of helmet therapy [2]. In the previ-
ous studies, the CVA, CVAI, cranial index, orbitotragial depth 
asymmetry (OTDA), and cranial base asymmetry (CBA) were 
used for the outcome analysis [6,8,14,16,19]. Moreover, the 
cosmetic outcome score based on the parent’s perception was 
also used [21]. Among these various measurements, we used 
CVA and CVAI because these were measured easily in the 
outpatient clinic using spreading calipers. Furthermore, a re-
cent study reported that the CVAI was a suitable measurement 
because it was independent of the head size [19]. Although 
experienced physicians measured the CVA and CVAI using 
a spreading caliper in this study, it was possible that the mea-
surement was changeable according to the patient’s position 
and motion [22,23]. Thus, more advanced methods such as 
three-dimensional surface scanning laser therapy [13], three-
dimensional photographic analysis [14], and a computer-aided 
design (CAD) system [2] have been introduced in recent stud-
ies, which could reduce such errors. 
Although many studies have reported good results of helmet 
therapy, none have addressed the best initiation age of the ther-
apy and the treatment period. In s previous study, the optimal 
time to start helmet therapy was months 5 to 6 of life according 
to the comparison of the treatment effect of two groups (one 
group started helmet therapy before 6 months of age and the 
other group started older than 6 months) [24]. However, in 
Fig. 5. Differences in the successful treatment rate accord-
ing to the duration of therapy
When the treatment period of the helmet therapy was 7.83 months, 
the area under the receiver operating characteristic curve was 0.607, 
which was in the 95% confidence interval 0.509 to 0.700. This means 
that the rate of successful treatment was statistically different above 
and below the point of 7.83 months (in other words, the patients 
who had worn the helmet more than 7.83 months showed a higher 
success rate than those who wore it less than 7.83 months).
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Fig. 4. Changes of the successful treatment rate according 
to the age of initiation of therapy
When the initiation age of the helmet therapy was 9.1 months, 
the area under the receiver operating characteristic curve was 
0.633, which was in the 95% confidence interval 0.535 to 0.724. 
This means that the rate of successful treatment was statistically 
different before and after the point of 9.1 months (in other words, 
the patients who started helmet therapy younger than 9.1 months 
showed a higher success rate than those who started older than 9.1 
months). 
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this study, we considered a final CVA ≤5 mm to be a successful 
outcome, and analysis of the change of success rate according to 
the initiation age and the treatment period. If the initiation age 
of the helmet therapy was older than 9.1 months, the rate of suc-
cessful treatment decreased significantly. According to previous 
reports, pediatric patients are started on helmet therapy for non-
synostotic plagiocephaly older than 4 months because sponta-
neous correction of skull asymmetry may be possible according 
to brain growth up to 4 months of age [15,20]. Thus treatment 
initiation between 4 and 9.1 months old is considered appropri-
ate. In the same way, the rate of successful treatment decreased 
significantly when the treatment period was shorter than 7.83 
months. 
Thus, according to the results of this study, we suggest a new 
strategy for helmet therapy. The strategy is that the therapy 
should be started between 4 and 9.1 months old, the treatment 
period should be more than 7.83 months, and the helmet wear-
ing time should be more than 20 hours a day (Table 4).
Of the 108 pediatric patients, 18 patients’ experience coin-
cided with this new treatment strategy. The mean initial diago-
nal A and B of the 18 patients were 145.9 mm and 130 mm, 
and the mean final diagonal A and B were 155.1 mm and 150.4 
mm. Based on these results, diagrammatic representation of the 
treatment effect of the treatment strategy is presented (Fig. 6). 
This helmet therapy strategy may be a practical guideline for the 
treatment for physicians and patients’ parents.
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Table 4. Helmet therapy strategy
Helmet therapy strategy
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Treatment period  ≥7.83 months
Helmet wearing time     ≥20 hours a day
fzB
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